These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 15784740)

  • 21. Ablating N-acetylaspartate prevents leukodystrophy in a Canavan disease model.
    Guo F; Bannerman P; Mills Ko E; Miers L; Xu J; Burns T; Li S; Freeman E; McDonough JA; Pleasure D
    Ann Neurol; 2015 May; 77(5):884-8. PubMed ID: 25712859
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolic changes in the knockout mouse for Canavan's disease: implications for patients with Canavan's disease.
    Surendran S; Matalon KM; Szucs S; Tyring SK; Matalon R
    J Child Neurol; 2003 Sep; 18(9):611-5. PubMed ID: 14572139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Myelin lesion in the aspartoacylase (Aspa) knockout rat, an animal model for Canavan disease.
    Takeda S; Hoshiai R; Tanaka M; Izawa T; Yamate J; Kuramoto T; Kuwamura M
    Exp Anim; 2024 Jul; 73(3):347-356. PubMed ID: 38538326
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aspartoacylase is restricted primarily to myelin synthesizing cells in the CNS: therapeutic implications for Canavan disease.
    Kirmani BF; Jacobowitz DM; Kallarakal AT; Namboodiri MA
    Brain Res Mol Brain Res; 2002 Nov; 107(2):176-82. PubMed ID: 12487123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease?
    Baslow MH; Guilfoyle DN
    Neurochem Res; 2009 Sep; 34(9):1523-34. PubMed ID: 19319678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aspartoacylase deficiency affects early postnatal development of oligodendrocytes and myelination.
    Mattan NS; Ghiani CA; Lloyd M; Matalon R; Bok D; Casaccia P; de Vellis J
    Neurobiol Dis; 2010 Nov; 40(2):432-43. PubMed ID: 20637282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain.
    Mathew R; Arun P; Madhavarao CN; Moffett JR; Namboodiri MA
    J Pharmacol Exp Ther; 2005 Oct; 315(1):297-303. PubMed ID: 16002461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The neuronal metabolite NAA regulates histone H3 methylation in oligodendrocytes and myelin lipid composition.
    Singhal NK; Huang H; Li S; Clements R; Gadd J; Daniels A; Kooijman EE; Bannerman P; Burns T; Guo F; Pleasure D; Freeman E; Shriver L; McDonough J
    Exp Brain Res; 2017 Jan; 235(1):279-292. PubMed ID: 27709268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of localized proton nuclear magnetic resonance spectroscopy in Canavan's disease.
    Aydinli N; Calişkan M; Calay M; Ozmen M
    Turk J Pediatr; 1998; 40(4):549-57. PubMed ID: 10028864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developmental increase of aspartoacylase in oligodendrocytes parallels CNS myelination.
    Kirmani BF; Jacobowitz DM; Namboodiri MA
    Brain Res Dev Brain Res; 2003 Jan; 140(1):105-15. PubMed ID: 12524181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms.
    Baslow MH; Resnik TR
    J Mol Neurosci; 1997 Oct; 9(2):109-25. PubMed ID: 9407392
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Defective myelin lipid synthesis as a pathogenic mechanism of Canavan disease.
    Namboodiri AM; Moffett JR; Arun P; Mathew R; Namboodiri S; Potti A; Hershfield J; Kirmani B; Jacobowitz DM; Madhavarao CN
    Adv Exp Med Biol; 2006; 576():145-63; discussion 361-3. PubMed ID: 16802710
    [No Abstract]   [Full Text] [Related]  

  • 33. Aspartoacylase-lacZ knockin mice: an engineered model of Canavan disease.
    Mersmann N; Tkachev D; Jelinek R; Röth PT; Möbius W; Ruhwedel T; Rühle S; Weber-Fahr W; Sartorius A; Klugmann M
    PLoS One; 2011; 6(5):e20336. PubMed ID: 21625469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
    Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
    J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative computational assessment of the pathogenicity of mutations in the Aspartoacylase enzyme.
    George Priya Doss C; Zayed H
    Metab Brain Dis; 2017 Dec; 32(6):2105-2118. PubMed ID: 28879565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion.
    Di Pietro V; Cavallari U; Amorini AM; Lazzarino G; Longo S; Poggiani C; Cavalli P; Tavazzi B
    Clin Biochem; 2013 Dec; 46(18):1902-4. PubMed ID: 24036223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brain Nat8l Knockdown Suppresses Spongiform Leukodystrophy in an Aspartoacylase-Deficient Canavan Disease Mouse Model.
    Bannerman P; Guo F; Chechneva O; Burns T; Zhu X; Wang Y; Kim B; Singhal NK; McDonough JA; Pleasure D
    Mol Ther; 2018 Mar; 26(3):793-800. PubMed ID: 29456021
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Upregulation of N-acetylaspartic acid resulting nitric oxide toxicity induces aspartoacylase mutations and protein interaction to cause pathophysiology seen in Canavan disease.
    Surendran S
    Med Hypotheses; 2010 Dec; 75(6):533-4. PubMed ID: 20673702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Canavan disease, a rare early-onset human spongiform leukodystrophy: insights into its genesis and possible clinical interventions.
    Baslow MH; Guilfoyle DN
    Biochimie; 2013 Apr; 95(4):946-56. PubMed ID: 23151389
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Canavan disease: studies on the knockout mouse.
    Matalon R; Michals-Matalon K; Surendran S; Tyring SK
    Adv Exp Med Biol; 2006; 576():77-93; discussion 361-3. PubMed ID: 16802706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.